Relacorilant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Relacorilant
- Molecular weight
- 586.57
- Structure (SMILES)
- Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
- (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE
- cort 125134
- Cort 125134
- Cort-125134
- cort125134
- CORT125134
- cort125134 150 mg
- CORT125134 150 mg
- cort125134 250 mg
- CORT125134 250 mg
- lifyorli
- LIFYORLI
- r 1 4 fluorophenyl 6 1 methyl 1h pyrazol 4 yl sulfonyl 1 4 5 6 7 8 hexahydro 4ah pyrazolo 3 4 g isoquinolin 4a yl 4 trifluoromethyl pyridin 2 yl methanone
- relacorilant
- Relacorilant
- Relacorilant (3x100 mg hard-shell capsules)
- Relacorilant (3x100 mg softgel capsules)
- Relacorilant (6x50mg hard-shell capsules)
- relacorilant [INN]
- RELACORILANT [USAN]
- Relacorilant [WHO-DD]
- relacorilant 150 mg
- Relacorilant 150 mg
- relacorilant 300mg
- Relacorilant 300mg
And 9 more, listed on the interactive page.
- CAS registry numbers
- 1496510-51-0
- ChEMBL ID
- CHEMBL4068611
- InChIKey
- WANIDIGFXJFFEL-SANMLTNESA-N
- PubChem compound IDs
- 73051463
- RxNorm IDs (RxCUI)
- 2739519
- FDA ingredient codes (UNII)
- 2158753C7E
- Status
- opinion
- Status date
- 17 Sept 2026
- Approved indications
- Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Product number
- EMEA/H/C/006731
- Authorisation holder
- Corcept Therapeutics Netherlands B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
European medicines record
- Patents
- 10
- Designations
- 1
- Earliest recorded loss of exclusivity
- 22 Dec 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- Yes
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- European Union (EMA)
- Opinion adopted, decision pending
- Pharmacology name
- relacorilant
- Type
- Synthetic organic
- Drug name stem
- -corilant
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 8.14
- Affinity units
- pKi
- Mechanism
- Glucocorticoid receptor antagonist
- Action type
- Antagonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor antagonist
- Action type
- Antagonist
- Target
- Glucocorticoid receptor
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Cushing Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003099
- Subject identifier
- D003480
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000251
- Subject identifier
- D005185
- Condition
- Adrenal Cortex Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000796
- Subject identifier
- D000306
- Condition
- Adrenocortical Hyperfunction
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000797
- Subject identifier
- D000308
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003099
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000797
- Highest recorded phase
- 3
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- HP_0040270
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001416
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006639
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006640
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007079
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018364
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018479
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018912
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0957431
- Highest recorded phase
- 2
- NCT02762981
- NCT02804750
- NCT03604198
- NCT03697109
- NCT03674814
- NCT05726292
- NCT03776812
- NCT04308590
- NCT04329949
- NCT04373265
- NCT06094725
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 0
- Polar surface area
- 102.98
- Calculated partition coefficient (ALogP)
- 4.06
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 5
- Heavy atoms
- 41
- Molecular formula
- C27H22F4N6O3S
- Monoisotopic mass
- 586.14102241
- Natural product
- No
- Recorded assays
- 170
- Active assays
- 13
Active assay types
- Confirmatory
- Antineoplastic Agents
These details could not be displayed.
Related records
Trials (25)
- A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
- A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
- A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
- A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
- A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
- CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
- Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer
- Relacorilant Food Effect Study in Healthy Subjects
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
- Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
- Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
In development for (20)
- Adrenal cortex carcinoma Phase 1
- Adrenal gland hyperfunction Phase 3
- Congenital adrenal hyperplasia Phase 3
- Cushing syndrome Phase 3
- Endogenous Cushing syndrome Phase 2
- Fallopian tube cancer Phase 3
- Fallopian tube carcinoma Phase 2
- Female reproductive organ cancer Phase 2
- Hypertensive disorder Phase 3
- Liver disorder Phase 1
- Malignant epithelial tumor of ovary Phase 3
- Neoplasm Phase 1
- Ovarian cancer Phase 2
- Ovarian carcinoma Phase 3
- Pancreatic adenocarcinoma Phase 2
- Pancreatic ductal adenocarcinoma Phase 3
- Primary peritoneal carcinoma Phase 3
- Prostate adenocarcinoma Phase 2
- Prostate cancer Phase 2
- Type 2 diabetes mellitus Phase 3
Other linked conditions (1)
- Alcohol dependence
Targets (1)
- NR3C1 Glucocorticoid receptor antagonist